| Field | Specification |
|---|---|
| Mfr No | |
| Activity | |
| Alternative Names | Anthra(1,9-cd)pyrazol-6(2H)-one, 1,9-Pyrazoloanthrone |
| Cas No. | |
| Form | Yellow to brown solid |
| Molecular Weight | |
| Product Type | |
| Purity | |
| Shipping | |
| SMILES | |
| Solubility | Soluble in DMSO or methanol |
| Source | Synthetic |
| Storage |
SP600125 is a selective, reversible inhibitor of c-Jun N-terminal kinases (JNK1, JNK2, and JNK3), with IC50 values ranging from 40 to 90 nM. JNK signaling is implicated in neuronal apoptosis, neuroinflammation, and synaptic dysfunction—hallmarks of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. SP600125 is frequently used to dissect the role of JNK in neuronal cell death pathways and to evaluate neuroprotective strategies. Although it exhibits reduced selectivity under certain conditions, its in vivo activity and minimal off-target effects on ERK2 and p38β make it a valuable tool for studying stress-activated kinase signaling in the brain. SP600125 has also shown protective effects in models of ischemia-reperfusion injury, supporting its relevance in stroke and neurovascular research.
Classification: D2B - Toxic Material Causing Other Toxic Effects, Moderate skin irritant, Moderate respiratory irritant, Moderate eye irritant
Safety Phrases:
- S22 - Do not breathe dust
- S24/25 - Avoid contact with skin and eyes
- S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection
Hazard Phrases:
- H315 - Causes skin irritation.
- H319 - Causes serious eye irritation.
- H335 - May cause respiratory irritation
Precautionary Phrases:
- P261 - Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
- P264 - Wash skin thoroughly after handling.
- P271 - Use only outdoors or in a well-ventilated area.
- P280 - Wear protective gloves/ eye protection/ face protection.
- P302 + P352 - IF ON SKIN: Wash with plenty of soap and water.
- P304 + P340 - IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
- P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- P312 – Call a POISON CENTER or doctor/ physician if you feel unwell.
- P321 - Specific treatment (see supplemental first aid instructions on this label).
- P332 + P313 - If skin irritation occurs: Get medical advice/ attention.
- P337 + P313 - If eye irritation persists: Get medical advice/ attention.
- P362 - Take off contaminated clothing and wash before reuse.
- P403 + P233 - Store in a well - ventilated place. Keep container tightly closed.
- P405 - Store locked up.
- P501 - Dispose of contents/ container to an approved waste disposal plant.
SP600125 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-381)
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close
equivalents, or discuss custom synthesis with the right QC documentation (RUO).
2. Schnabl B., et al. (2001) Hepatology. 34(5): 953-63.
3. Bain J., et al. (2003) Biochem. J. 371(Pt 1): 199-204.
4. Wang Y., et al. (2007) Life Sci. 80(22): 2067-75.